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USPSTF Updates Recommendation
for Obstructive Sleep Apnea Screening in Adults
Kathleen Yaremchuk, MD, MSA

The US Preventive Services Task Force (USPSTF) was created
in 1984 as an independent, volunteer panel of national experts in prevention and evidence-based medicine. It works to
improve the health of all persons in the US by making recommendations about clinical preventive services such as screenings, counseling services, and preventive medications.1
The 2022 USPSTF obstructive sleep apnea (OSA) screening recommendation,2 supported by an updated evidence report and systematic review,3 applies to asymptomatic adults
18 years or older. It also applies to adults with unrecognized
symptoms of OSA but does
not apply to persons presentMultimedia
ing with symptoms (eg, snoring, witnessed apnea, excessive daytime sleepiness,
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impaired cognition, mood
jama.com
changes, gasping or choking
while asleep) or concerns about OSA, persons who have been
referred for evaluation or treatment of suspected OSA, or persons who have acute conditions that could trigger the onset
of OSA (eg, stroke). Risk factors associated with OSA were male
sex, older age (40-70 years), postmenopausal status, higher
body mass index, and craniofacial and upper airway abnormalities (eg, enlarged tonsils or long upper airway).2
Research methods for the recommendation had 2 investigators independently selecting English-language studies using
a priori criteria.3 Eligible studies included randomized clinical trials (RCTs) of screening for or treatment of OSA reporting on health outcomes, studies evaluating accuracy of screening questionnaires or clinical prediction tools in asymptomatic
adults with OSA or persons with unrecognized symptoms of
OSA, and systematic reviews of treatment reporting on changes
in blood pressure and apnea-hypopnea index (AHI) scores.
The USPSTF recommendation is unchanged from 2017 and
concludes that the current evidence is insufficient to assess
the balance of benefits and harms of screening for OSA in the
general adult population.2 The decision was given an I statement, which indicates insufficient evidence (Table).3
Screening questionnaires and clinical prediction tools such
as the Epworth Sleepiness Scale (ESS), STOP (Snoring, Tiredness, Observed Apnea, High Blood Pressure) questionnaire,
STOP-BANG (STOP questionnaire plus Body Mass Index, Age,
Neck Circumference, and Gender) questionnaire, Berlin questionnaire, Wisconsin sleep questionnaire, and the Multivariable Apnea Prediction tool have not been validated in general
populations enrolled from primary care settings, so they are
not adequate in a primary care practice for purposes of screening. The USPSTF found no studies that evaluated the effect of
jamaotolaryngology.com

Table. US Preventive Services Task Force Grades
Grade

Definition

A

Recommended

B

Recommended

C

Recommendation depends on the patient’s situation

D

Not recommended

I statement

There is not enough evidence to make a recommendation

screening for OSA on health outcomes, though it did identify
and review studies on the effect of treatment on health and
intermediate outcomes.
Treatment modalities were evaluated for primary outcome
(eg, an improvement in health outcomes). Obstructive sleep apnea has been associated with cardiovascular disease (eg, coronary
heart disease, stroke, hypertension, type 2 diabetes, metabolic
syndrome). Although OSA is associated with increased all-cause
mortality, the role OSA plays in increasing overall mortality independent from other risk factors (eg, older age, higher body mass
index, other cardiovascular risk factors) is less clear.
Studies included evaluated intermediate outcomes such as
changes in AHI, blood pressure, and ESS score. In 2017, RCTs involving positive airway pressure (PAP) showed that treatment
of OSA with continuous PAP and mandibular advancement devices (MADs) improved intermediate outcomes, such as AHI,
blood pressure, and ESS score, though there are no studies demonstrating that those changes improve health outcomes or are
clinically relevant.1 The screening guideline represents that there
are no well-controlled trials that have demonstrated an improvement in mortality with treatment of OSA.2
Unfortunately, the USPSTF only reviewed evidence evaluating the effect of PAP and MADs for treatment and outcomes.
Positive airway pressure was associated with small improvements in general health-related and sleep-related quality of life.
However, the improvements are not clinically meaningful. The
findings for MADs were inconsistent or imprecise, making it difficult to draw conclusions on the quality-of-life benefits.
Excluded from the analysis in 2017 and 20223 were any
studies evaluating upper airway surgery treatment or outcomes. The explanation for the omission is that “surgical interventions for OSA are available, but they generally are not
considered first-line treatments.”2 A 2010 study by Kezirian
et al that included data from 2006 to 2010 indicated that surgical treatment is performed in 0.2% of all adults with OSA annually, based on administrative data with inherent limitations.4
When the USPSTF released the 2022 recommendation2 for public comment, the American Academy of Otolaryngology–
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Head and Neck Surgery Sleep Disorders Committee submitted comments that strongly encouraged the USPSTF to include
upper airway surgery in treatments, health outcomes, and intermediate outcomes available in the literature.
A retrospective cohort study of a population of 21 000 US veterans with OSA who underwent uvulopalatopharyngoplasty
(UPPP) or used continuous PAP was adjusted for gender, race, and
comorbidities; the mortality rate for patients who underwent
UPPP was 30% lower for each of the 5 years of follow-up and
would be considered a health outcome improvement.5 A study
of the Korean national health insurance corporation database of
more than 200 000 patients with OSA evaluated the effectiveness of UPPP on major cardiovascular outcomes with 8 years of
follow-up.6 Patients undergoing UPPP (n = 22 000) demonstrated
a reduction in the incidence of myocardial infarction, congestive
heart failure (CHF), and atrial fibrillation (AF) compared with a
control population of 190 000 patients and 76 000 patients with
OSA who were untreated. Patients with OSA had an increased risk
of CHF and AF compared with control patients, and UPPP reduced
the incidence of CHF and AF considerably.

ARTICLE INFORMATION
Author Affiliation: Department of Otolaryngology–
Head & Neck Surgery, Henry Ford Health, Detroit,
Michigan.
Corresponding Author: Kathleen Yaremchuk, MD,
MSA, Department of Otolaryngology–Head & Neck
Surgery, Henry Ford Health, 2799 W Grand Blvd,
Detroit, MI 48202 (kyaremc1@hfhs.org).
Published Online: November 15, 2022.
doi:10.1001/jamaoto.2022.3844
Conflict of Interest Disclosures: None reported.
REFERENCES
1. US Preventive Services Task Force. Accessed
October 26, 2022. https://www.
uspreventiveservicestaskforce.org/uspstf/

E2

While not specific to otolaryngology, weight loss and bariatric surgery have been shown in a systematic review to improve OSA,7 but neither were included in the analysis.3 It appears that the USPSTF did not evaluate any studies that were
not RCTs or systematic reviews specific to PAP and MADs.
In summary, what is new in this update2 is that upper airway surgery was specifically mentioned as insignificant for
treatment and outcomes for OSA. This recommendation was
based on an article that 0.2% of patients with OSA received a
surgical procedure.4 What is not new is that in the analysis USPSTF performed it concluded that there was insufficient evidence to recommend screening of the general population for
OSA. The USPSTF was unable to find evidence of a validated
tool to screen for OSA in the general population, and there was
a lack of data to support treatment or evidence of improved
outcomes. Unfortunately, the only evidence reviewed by the
USPSTF was for PAP and MADs despite population-based studies that have reported favorable outcomes for surgery (upper
airway and bariatric) and weight loss in terms of treatment and
outcomes.

2. US Preventive Services Task Force. Screening for
obstructive sleep apnea in adults: US Preventive
Services Task Force recommendation statement.
JAMA. Published online November 15, 2022. doi:10.
1001/jama.2022.20304

5. Weaver EM, Maynard C, Yueh B. Survival of
veterans with sleep apnea: continuous positive
airway pressure versus surgery. Otolaryngol Head
Neck Surg. 2004;130(6):659-665. doi:10.1016/j.
otohns.2003.12.012

3. Feltner C, Wallace IF, Aymes S, et al. Screening
for obstructive sleep apnea in adults: updated
evidence report and systematic review for the US
Preventive Services Task Force. JAMA. Published
online November 15, 2022. doi:10.1001/jama.2022.
18357

6. Lee HM, Kim HY, Suh JD, et al.
Uvulopalatopharyngoplasty reduces the incidence
of cardiovascular complications caused by
obstructive sleep apnea: results from the national
insurance service survey 2007-2014. Sleep Med.
2018;45:11-16. doi:10.1016/j.sleep.2017.12.019

4. Kezirian EJ, Maselli J, Vittinghoff E, Goldberg
AN, Auerbach AD. Obstructive sleep apnea surgery
practice patterns in the United States: 2000 to
2006. Otolaryngol Head Neck Surg. 2010;143(3):
441-447. doi:10.1016/j.otohns.2010.05.009

7. Quintas-Neves M, Preto J, Drummond M.
Assessment of bariatric surgery efficacy on
Obstructive Sleep Apnea (OSA). Rev Port Pneumol
(2006). 2016;22(6):331-336. doi:10.1016/j.rppnen.
2016.05.006

JAMA Otolaryngology–Head & Neck Surgery Published online November 15, 2022 (Reprinted)

© 2022 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 12/21/2022

jamaotolaryngology.com

